A cikin 2025, Tirzepatide yana samun saurin girma a cikin sashin kula da cututtukan rayuwa na duniya. Tare da yawan kiba da ciwon sukari na ci gaba da hauhawa, da kuma haɓaka wayar da kan jama'a game da ingantaccen tsarin sarrafa rayuwa, wannan sabon aikin GLP-1 da GIP agonist yana haɓaka sawun kasuwar sa cikin sauri.
Eli Lilly, tare da samfuran sa Mounjaro da Zepbound, suna da matsayi mafi girma a duniya. An goyi bayan ingantaccen shaidar asibiti, ingancin Tirzepatide a cikin sarrafa glycemic, asarar nauyi, da kariyar zuciya da jijiyoyin jini an ƙara inganta. Sabbin bayanan asibiti na 2025 sun nuna cewa Tirzepatide ya zarce irin waɗannan kwayoyi wajen rage manyan haɗarin haɗarin cututtukan zuciya, tare da raguwar lambobi biyu a cikin mace-mace. Wannan ci gaban ba wai kawai yana haɓaka kwarin gwiwa na likita ba amma yana ƙarfafa shari'ar don ingantacciyar shawarwarin biyan kuɗi.
Ci gaban manufofin kuma suna cusa ɗorewa cikin ci gaban kasuwa. Gwamnatin Amurka ta sanar da shirye-shiryen hada magunguna masu rage nauyi, gami da Tirzepatide, karkashin tsarin Medicare da Medicaid wanda zai fara a cikin 2026. Wannan zai fadada damar yin haƙuri sosai, musamman a tsakanin al'ummomin masu tsada, haɓaka shigar kasuwa. A halin yanzu, yankin Asiya-Pacific yana fitowa a matsayin kasuwa mafi girma cikin sauri saboda gyare-gyaren kiwon lafiya, faffadan inshora, da kuma yawan jama'a.
Duk da haka, akwai kalubale. Babban farashin Tirzepatide-wanda yakan wuce $1,000 a kowane wata-ya ci gaba da iyakance karɓuwa da yawa inda inshora bai isa ba. Ƙididdiga na FDA bayan ƙarancin ƙayyadaddun abubuwan da aka haɗa su ma sun ƙara farashi ga wasu marasa lafiya, wanda ke haifar da dakatar da magani. Bugu da kari, illolin gama gari na gama gari masu alaƙa da magungunan GLP-1, tare da damuwa na ka'ida akan tashoshin tallace-tallace na kan layi, suna buƙatar kulawa mai gudana daga masana'antu da masu gudanarwa.
Ana sa ran gaba, yuwuwar ci gaban kasuwar Tirzepatide ya kasance mai mahimmanci. Tare da ƙarin nunin faɗaɗawa (misali, bacci mai hana bacci, rigakafin cututtukan zuciya), ɗaukar hoto mai zurfi, da ɗaukar kayan aikin sarrafa jiyya na dijital da shirye-shiryen tallafi na haƙuri, ana sa ran rabon Tirzepatide a cikin kasuwar magunguna na rayuwa ta duniya zai tashi a hankali. Ga 'yan wasan masana'antu, yin amfani da fa'idodin asibiti, inganta tsarin biyan kuɗi, da kuma tabbatar da matakin farko a kasuwanni masu tasowa zai zama mabuɗin cin nasara a gaba.
Lokacin aikawa: Agusta-05-2025